杀伤细胞免疫球蛋白样受体配体错配与移植后环磷酰胺单倍体移植后的结局
该研究纳入444例接受T细胞充足移植物联合移植后环磷酰胺(PTCy)单倍体移植的急性白血病患者,37%存在KIR配体错配。多因素分析显示KIR配体错配与更差生存相关(HR 1.41,P=0.03),并与复发升高趋势相关,但与移植物抗宿主病或非复发死亡无关。结论认为在PTCy背景下无证据表明KIR配体错配带来更好结局。
要点
- 444例急性白血病患者中37%存在KIR配体错配,2年生存率45.9%。
- KIR配体错配与更差生存相关(HR 1.41,P=0.03)。
- KIR配体错配与复发升高趋势相关,但与GVHD或NRM无关。
核心结论
- 在PTCy单倍体移植背景下,无证据表明KIR配体错配带来更好结局。
研究设计与样本
- 研究纳入444例接受T细胞充足移植物联合PTCy单倍体移植的急性白血病患者。
- 37%的患者存在KIR配体错配;患者处于第一次缓解(CR1)39%、第二次缓解(CR2)26%或活动性疾病35%。
- 干细胞来源为外周血(PBSC)46%或骨髓54%。
主要发现
- 2年复发率36.0%(95%CI 31.4-40.7),非复发死亡率23.9%(95%CI 20.0-28.0),生存率45.9%(95%CI 40.8-51.0)。
- 多因素分析显示急性髓系白血病相比急性淋巴细胞白血病(HR 0.55,P=0.002)、女性(HR 0.72,P=0.04)和良好体能状态(HR 0.71,P=0.04)与更好生存相关。
- 高龄(HR 1.13,P=0.04)、活动性疾病(HR 3.38,P<0.0001)和KIR配体错配(HR 1.41,P=0.03)与更差生存相关。
- KIR配体错配与复发升高趋势相关,但与移植物抗宿主病或非复发死亡无关。
- KIR配体错配效应在接受PBSC的患者中更明显。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haploidentical stem cell transplantation with T cell-replete grafts and post-transplant cyclophosphamide (PTCy) is increasingly used with encouraging outcome. Natural killer (NK) cell alloreactivity, predicted by missing killer cell immunoglobulin-like receptor (KIR) ligands in the recipient that are present in their donor improves outcome of T cell-depleted haploidentical transplants. We explored the role of KIR ligand mismatching in 444 acute leukemia patients after T cell-replete transplants with PTCy. Thirty-seven percent of all patients had KIR ligand mismatching. Patients were in first remission (CR1) (39%), second remission (CR2) (26%), or active disease (35%). Stem cell source was peripheral blood (PBSC, 46%) or bone marrow (54%). The 2-year relapse, non-relapse mortality (NRM), and survival rates were 36.0% (95% confidence interval (CI), 31.4-40.7), 23.9% (20.0-28.0), and 45.9% (40.8-51.0), respectively. Multivariate analysis identified acute myeloid leukemia compared with acute lymphoblastic leukemia (hazard ratio (HR) 0.55, P = 0.002), female gender (HR 0.72, P = 0.04), and good performance status (HR 0.71, P = 0.04) as factors associated with better survival, while advanced age (HR 1.13, P = 0.04), active disease (HR 3.38, P < 0.0001), and KIR ligand mismatching (HR 1.41, P = 0.03) as associated with worse survival. KIR ligand mismatching was associated with a trend for higher relapse but not with graft-versus-host disease or NRM. The KIR ligand-mismatching effect was more prominent in patients given PBSC. In conclusion, there is no evidence that KIR ligand mismatching results in better outcome in the PTCy setting.
引用
- Shimoni A, Labopin M, Lorentino F, et al. Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. Leukemia. 2018. PMID: 29907809. doi:10.1038/s41375-018-0170-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。